Clinical Trials
23 trialsNCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT04270175 2026-02-27
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT07335887 2026-01-13
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT03618537 2025-12-04
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04304144 2025-03-05
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 2 Completed
NCT06342466 2024-12-30
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Peking University People's Hospital
Phase 2 Recruiting
NCT05066607 2024-03-06
IsAMYP
Intergroupe Francophone du Myelome
Phase 2 Unknown
NCT00520767 2023-12-22
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT03252600 2023-01-25
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
Phase 2 Unknown
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT04474938 2022-05-10
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
Phase 2 Unknown
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT01222260 2020-03-30
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Columbia University
Phase 2 Completed
NCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT01510613 2018-03-12
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Completed
NCT01194791 2017-04-25
LENDEXAL
PETHEMA Foundation
Phase 2 Completed
NCT00091260 2017-02-20
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00679367 2017-02-20
MRD
Boston Medical Center
Phase 2 Completed
NCT00458822 2016-08-10
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002849 2015-03-06
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT01072773 2014-04-02
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Mayo Clinic
Phase 2 Completed
NCT00564889 2013-05-14
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 2 Completed
NCT00089167 2013-01-16
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed